President Trump signs executive order expediting marijuana reclassification to Schedule III, delivering medical relief to millions while rejecting full recreational legalization—a win for science-driven compassion over elite-driven overreach.
Story Highlights
- Trump directs Attorney General to fast-track rescheduling from Schedule I (no medical use) to Schedule III (accepted medical benefits, like Tylenol with codeine), based on HHS/FDA science.
- Action aids 6M+ patients and 30,000+ practitioners treating 15+ conditions like pain, chemotherapy nausea, and anorexia, aligning federal law with 38+ state programs.
- No recreational legalization; focuses on research expansion, youth protections, and regulated CBD/hemp with THC limits to prevent abuse.
- Builds on 2023-2024 reviews stalled under prior administration; Trump’s order resumes DOJ rulemaking amid 43,000 public comments.
- Bipartisan frustration with federal gridlock met by executive action prioritizing patients over bureaucracy.
Executive Order Accelerates Long-Overdue Reform
On December 18-19, 2025, President Trump signed an executive order directing the Attorney General to complete rulemaking for rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. Schedule I groups it with heroin, claiming no medical use despite state laws serving millions. This directive mandates the “most expeditious” process per federal law, building on HHS and FDA recommendations. Trump emphasized his passion for patients, flanked by medical professionals during the Oval Office signing. The move recognizes credible science for treatments like chronic pain and chemotherapy side effects, easing tensions between federal prohibition and state realities. Conservatives applaud limited government yielding to evidence, not elite mandates.
BREAKING: Trump administration reclassifies medical marijuana under federal law.
Acting AG Todd Blanche signed the order shifting it from SCHEDULE I, a category of drugs with no medical use and high potential for abuse, to the much less strictly regulated SCHEDULE III.
While… pic.twitter.com/RdwcKQVw3r
— Fox News (@FoxNews) April 23, 2026
Scientific Foundation from HHS and FDA Reviews
HHS determined marijuana has accepted medical uses, citing over 30,000 licensed practitioners recommending it to more than 6 million patients across 43 jurisdictions for at least 15 conditions. FDA found scientific support for pain management, anorexia in certain illnesses, and nausea/vomiting from chemotherapy. NIDA concurred with the Schedule III recommendation in 2023. The May 2024 DOJ proposed rule drew nearly 43,000 public comments but awaited an administrative hearing. Trump’s order revives this stalled process, distinct from Biden-era delays. This evidence-based shift frustrates deep state inertia, empowering doctors and patients over Washington bureaucrats. Both sides weary of federal failures see hope in action over endless talk.
Key Stakeholders Drive Patient-Centered Change
President Trump leads with Secretary Kennedy, likely RFK Jr. at HHS, pushing for medical access and data collection on real-world outcomes. Core agencies—HHS, FDA, DEA, DOJ, NIDA—execute: HHS/FDA provided the science, DOJ handles rulemaking. ACLU policy counsel Nina Patel hailed it as aligning federal policy with science and states. Healthcare providers seek harmony after decades of conflict since California’s 1996 medical law. Power rests with the executive branch pressuring agencies, collaborating with Congress on hemp. This counters elite priorities, focusing on American families denied relief by outdated 1970s classifications amid bipartisan distrust of D.C. insiders.
The order also addresses CBD and hemp, mandating frameworks with THC limits, CBD:THC ratios, and research by HHS, FDA, CMS, NIH. Full-spectrum CBD products exceeding new thresholds fall under controls, tackling mislabeled items posing consumer risks. The 2018 Farm Bill legalized hemp under 0.3% THC, exploding the CBD market without safeguards. Trump’s directive provides clarity, protecting youth from overdoses while enabling safe medical innovation.
Impacts Bridge Federal-State Divide Without Full Legalization
Short-term effects include eased research barriers, banking access, and tax relief for state-licensed medical operations previously hit by Schedule I rules. Schedule III finalization could occur in months, enabling FDA approvals and insurance coverage long-term. Over 6 million patients gain federal recognition; cannabis firms see research boosts but hemp/CBD sellers face stricter THC rules. Economically, it expands markets; socially, it reduces stigma for epilepsy and pain sufferers. Politically, it’s a bipartisan bridge amid shared anger at government failure—Democrats obstructing, yet reform cuts through for everyday Americans chasing the Dream despite elite corruption.
Trump’s video stressed doctor-recommended uses and youth safeguards, balancing “miraculous effects” with abuse risks via data mandates. Unlike recreational pushes, this prioritizes medical evidence, distinguishing Trump’s America First realism from globalist overreach or woke excess. Conservatives value the restraint: liberty for patients, limits on vice.
Sources:
ACLU Responds to President Trump’s Announcement Rescheduling Marijuana
Increasing Medical Marijuana and Cannabidiol Research – White House
